Business
Rybrevant (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Key opportunities include increasing demand for personalized cancer therapies, growth in genomic testing, innovation in targeted treatments for NSCLC, and expansion of combination regimens. Strong potential lies in enhancing antibody-based solutions and establishing localized biologics manufacturing to offset tariff impacts.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Rybrevant Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarke
About this update from Johnson & Johnson
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"Key opportunities include increasing demand for personalized cancer therapies, growth in genomic testing, innovation in targeted treatments for NSCLC, and expansion of combination regimens. Strong potential lies in enhancing antibody-based solutions and establishing localized biologics manufacturing to offset tariff impacts.","length":326,"tagName":"p"},{"type":"text","content":"Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Rybrevant Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.","length":211,"tagName":"p"},{"type":"text","content":"The Rybrevant market is poised for significant growth driven by a surge in non-small cell lung cancer (NSCLC) occurrences, advancements in molecular diagnostics, and expanded approval for targeted oncology drugs. Historically, growth has been fueled by these factors, and looking forward, the demand for personalized cancer treatments and genomic testing in oncology will further boost market expansion. Increasing investments in biologic drug development and the adoption of combination cancer therapies are key drivers along with ongoing innovation in antibody-based treatments.","length":580,"tagName":"p"},{"type":"text","content":"Rybrevant, known scientifically as amivantamab, is aimed at treating NSCLC with specific EGFR mutations. The Canadian Cancer Society reported a rise in lung cancer cases in 2024, highlighting the urgency in effective treatment solutions. With the bispecific antibody Rybrevant, Johnson & Johnson achieved FDA approval for specific EGFR mutations, offering improved therapeutic options compared to traditional chemotherapy, resulting in enhanced progression-free survival.","length":475,"tagName":"p"},{"type":"text","content":"Janssen-Cilag's strategic partnership...